Follow-Up Study Confirms Safety, Efficacy of Neoadjuvant Immunotherapy in Resectable Cutaneous Melanoma

Source: Oncology Nurse Advisor, July 2023

Study with longer follow-up confirms outcomes of neoadjuvant plus adjuvant programmed cell death receptor 1 (PD-1) inhibition with resection in patients with resectable stage III/IV cutaneous melanoma, according to a study recently published in the Annals of Oncology.

Researchers embarked upon a follow-up study to a phase Ib clinical trial with 30 patients with resectable stage III/IV cutaneous melanoma. The patients had received 1 dose of neoadjuvant therapy (pembrolizumab 200 mg intravenously) 3 weeks before undergoing surgery, then 1 year of adjuvant therapy (pembrolizumab 200 mg IV every 3 weeks).

Previous studies had included limited follow-up periods, so the researchers set out to analyze results over a longer period of time. The primary outcomes for this study were 5-year overall survival (OS), 5-year recurrence-free survival (RFS), and recurrence patterns.